Caner Acar

Ege, Turkey

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 31 publications

Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world pan-cancer cohort.

Seasonal timing of anti-PD-1 therapy and survival outcomes in a real-world pan-cancer cohort.

Journal: Expert review of clinical immunology
Published: June 03, 2026

Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours.

Evaluating oral nutritional support and the nutritional risk scores in ICI-treated metastatic solid tumours.

Journal: Immunotherapy
Published: April 20, 2026

HIV Seroprevalence and Screening Practices Among Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Study From Türkiye.

HIV Seroprevalence and Screening Practices Among Cancer Patients Receiving Immune Checkpoint Inhibitors: A Single-Center Study From Türkiye.

Journal: Journal of clinical practice and research
Published: February 25, 2026

Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events.

Effect of steroid therapy on survival in patients with metastatic solid tumors experiencing immune-related adverse events.

Journal: Expert review of anticancer therapy
Published: January 08, 2026

Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors.

Pretreatment hyperferritinaemia as an independent prognostic marker in metastatic solid tumors treated with immune checkpoint inhibitors.

Journal: Expert review of anticancer therapy
Published: December 10, 2025

Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group.

Ten-year risk of second primary malignancies among chemotherapy-treated early-stage breast cancer survivors: a multicentre cohort study from the Turkish Oncology Group.

Journal: Frontiers in oncology
Published: November 28, 2025

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group.

Journal: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Published: November 14, 2025

Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment.

Using routine blood tests to predict severe immune-related adverse events during immune checkpoint inhibitor treatment.

Journal: BMC cancer
Published: October 02, 2025

XGBoost outperforms other machine learning models in diagnosing Sepsis-Associated Thrombocytopenia: a multicenter retrospective study.

XGBoost outperforms other machine learning models in diagnosing Sepsis-Associated Thrombocytopenia: a multicenter retrospective study.

Journal: Frontiers in medicine
Published: September 29, 2025

Dynamic lactate dehydrogenase/lymphocyte ratio and C-reactive protein as predictors of mortality after plasma exchange in ANCA-associated vasculitis: A retrospective case control study.

Dynamic lactate dehydrogenase/lymphocyte ratio and C-reactive protein as predictors of mortality after plasma exchange in ANCA-associated vasculitis: A retrospective case control study.

Journal: Medicine
Published: August 14, 2025

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Efficacy and safety of doxorubicin-ifosfamide versus gemcitabine-docetaxel as first-line therapy in advanced nonuterine leiomyosarcoma: A multicenter real-world study.

Journal: International journal of cancer
Published: August 13, 2025

Association between immune-related adverse events and recurrence dynamics under adjuvant anti-PD-1 therapy in resected melanoma.

Association between immune-related adverse events and recurrence dynamics under adjuvant anti-PD-1 therapy in resected melanoma.

Journal: Frontiers in oncology
Published: July 22, 2025
Showing 1-12 of 31

Last Updated: 09/26/2026